These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 16689077)
1. A better option? Gorman C Time; 2006 May; 167(18):70. PubMed ID: 16689077 [No Abstract] [Full Text] [Related]
2. Raloxifene (Evista) for breast cancer prevention in postmenopausal women. Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245 [TBL] [Abstract][Full Text] [Related]
3. [Chemoprevention of breast cancer. Impact of a new therapeutic strategy]. Kattan J; Ghosn M J Med Liban; 1999; 47(5):284-5. PubMed ID: 10887527 [No Abstract] [Full Text] [Related]
4. Chemoprevention of breast cancer: recommendations and rationale. Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459 [No Abstract] [Full Text] [Related]
5. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. Bevers TB J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929 [TBL] [Abstract][Full Text] [Related]
6. The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer. Kelminski A Hawaii Med J; 2002 Sep; 61(9):209-10. PubMed ID: 12422387 [No Abstract] [Full Text] [Related]
7. The changing perspective on breast cancer and chemotherapy. Three new developments are better able to predict breast cancer recurrence and chemotherapy effectiveness. Health News; 2006 Aug; 12(8):14-5. PubMed ID: 16913035 [No Abstract] [Full Text] [Related]
8. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Jordan VC Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908 [No Abstract] [Full Text] [Related]
9. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint. Fabian C Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909 [No Abstract] [Full Text] [Related]
11. Raloxifene works as well as tamoxifen in preventing invasive breast cancer. Mayo Clin Womens Healthsource; 2006 Oct; 10(10):3. PubMed ID: 16977270 [No Abstract] [Full Text] [Related]
12. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs. Vastag B J Natl Cancer Inst; 2006 Jun; 98(11):733-5. PubMed ID: 16757696 [No Abstract] [Full Text] [Related]
13. Bone builder vs. breast cancer. Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491 [No Abstract] [Full Text] [Related]
14. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs). Powles TJ Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068 [TBL] [Abstract][Full Text] [Related]
15. [Breast cancer chemoprevention. Rational, trials results and future]. Cutuli B; Lesur A; Namer M; Kerbrat P Bull Cancer; 2009 May; 96(5):519-30. PubMed ID: 19467983 [TBL] [Abstract][Full Text] [Related]
16. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Ganz PA; Land SR Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601 [TBL] [Abstract][Full Text] [Related]
17. A STAR is born. Jordan VC Oncology (Williston Park); 2006 Aug; 20(9):1126. PubMed ID: 16986351 [No Abstract] [Full Text] [Related]
18. Tamoxifen: to use or not to use. Yin CS Taiwan J Obstet Gynecol; 2008 Mar; 47(1):129-30. PubMed ID: 18400603 [No Abstract] [Full Text] [Related]
19. The current status of breast cancer chemoprevention: a star is born. Morrow M; Jordan VC J Surg Oncol; 2007 Jan; 95(1):4-5. PubMed ID: 17192883 [No Abstract] [Full Text] [Related]
20. Translating trial data into patients benefits: making the right choice. Chlebowski RT Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]